Prevalence of Hepatopancreatic Injury and Clinical Outcomes in Patients with COVID-19 in USA

Division

North Florida

Hospital

Ocala Regional Medical Center

Document Type

Manuscript

Publication Date

11-6-2021

Keywords

sars-cov-2, coronavirus infections, COVID-19, hepatopancreatic injury, liver, pancreas, mortality

Disciplines

Digestive System Diseases | Emergency Medicine | Virus Diseases

Abstract

Background

(1) To determine the prevalence of hepatopancreatic injury in coronavirus disease 2019 (COVID-19) patients. (2) To correlate hepatopancreatic injury in COVID-19 with mortality, disease severity, and length of stay in this cohort.

Results

Forty-five thousand three hundred sixty patients were included in the analysis, 62.82% of which had either hepatic or pancreatic injury. There was a significant upward trend in transaminases, alkaline phosphatase, prothrombin time, bilirubin, lactate dehydrogenase, and lipase and a downward trend in albumin with an increase in disease severity. COVID-19-positive patients with hepato-pancreatic injury have a significantly higher mortality (OR 3.39, 95%CI 3.15–3.65) after controlling for the differences in age, sex, race/ethnicity, liver cirrhosis, and medication exposures. They also have increased disease severity (OR 2.7, 95%CI 2.5–2.9 critical vs mild/moderate; OR 1.4, 95% CI 1.3–1.5 severe vs mild/moderate) and longer hospital length of stay (2 days).

Conclusion

COVID-19 can cause liver injury. Mortality, disease severity, and hospital length of stay are increased in COVID-19 patients with hepatopancreatic injury.

Publisher or Conference

International Journal of Emergency Medicine

Link to Full Text

Share

COinS